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Discussion 
Although multiresistant P.  faldipamm is an increasing 
problem, reports of P .  vivax resistant to chloroquine 
have been few. The above case reports document the 
presence of chloroquine-resistant P.  vivax in India, and 
show that it may not be as rare as it i s  presumed to be. 
Also, the number of drug resistant strains is probably in- 
creasing. Antimalarial drugs other than chloroquine used 
for P.  vivax have limitations of their own: sulfadoxine- 
pyrimethamine is not as effective as chloroquine, quinine 
is difficult to administer, and tetracyclines are contra- 
indicated in children and pregnant women and are not 
tolerated by many patients. Non-availability and cost 
limits the use of mefloquine and halofantrine. 
Further population-based epidemiological studies will 
be needed to define the extent of chlofoquine resistant 
P. vivax and identify suitable alternative treatments. If 
this problem were to become widespread, there would be 
significant implications for the treatment and prophy- 
laxis of malaria in India. 
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Antimalarial chemoprophylaxis is one of the important 
means to protect nonimmune travellers visiting malaria 
endemic areas. At present, there is no consensus on the 
prophylactic regimens, especially for West and Central 
Africa, where chloroquine resistance is present but is 
generally of low level (type RI and RII). The World 
Health Organization (WHO) and the American Centers 
for Disease Control recommend mefloquine for most of 
sub-Saharan Africa (CDC, 1990; WHO, 1995). Euro- 
pean experts generally recommend either mefloquine or 
chloroquine plus proguanil, on a case-to-case basis, for 
Central and West Africa (BRADLEY & WARHURST, 1995; 
CSHP, 1995). For East Africa, it is generally agreed that 
mefloquine is the drug of choice. Whether chloroquine 
plus proguanil or mefloquine should be prescribed for 
Central and West Africa is still debated, largely because 
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eroon. 
no randomized, prospective study on the effectiveness of 
these 2 regimens has been conducted. 
Previous studies have been based &-I retrospective 
questionnaires distributed to returning travellers or 
Peace Corps volunteers (LOBEL et al., 1993; STEFFEN et 
al., 1993). These investigators have concluded that me- 
floquine is well tolerated and more effective than chloro- 
quine plus proguanil for chemoprophylaxis in travellers 
visiting Africa. However, the design of these studies can- 
not lead to firm conclusions due to the subjective answers 
of the tourists to questionnaires concerning compliance, 
tolerance, and effectiveness and the statistical bias in- 
volving a significantly smaller sample size for the chloro- 
quine-proguanil group. 
Another indirect approach to evaluate the efficacy of 
antimalarial drugs is the determination of their activity in 
vitro against fresh clinical isolates of Plasmodium falcipa- 
rum. Between 1992 and 1994, we have analysed the drug 
sensitivity patterns of more than 300 isolates obtained 
from malaria-infected travellers returning to France from 
sub-saharan Africa, mostly from the francophone coun- 
tries in central and western parts of the continent. The 
activity in vitro of chloroquine, cycloguanil (biologically 
active metabolite of proguanil), and mefloquine was 
determined using the isotopic semi-microtest (BASCO et 
al., 1994). Based on previous in vitrolin vivo correlation 
studies (LE BRAS & RINGWALD, 1990), the threshold 
50% inhibitory concentration ( Ich)  value for resistance 
to chloroquine was set at 100 nivi. The threshold value 
for cycloguanil resistance was fmed at 50 nM (BASCO et 
al., 1994). Most malaria-infected patients receiving cor- 
rect chloroquine-proguanil prophylaxis provide isolates 
with cycloguanil IC50 values above this threshold value. 
The cut-off value for mefloquine resistance was esti- 
mated to be >30 nM, based on the analysis of drug sensi- 
Table. Proportion of drug-resistant Plasmodium fakiparum 
isolates from sub-Saharan Africa between 1992 and 1994 
Resistance to Central Africa West Africa 
61/97 63% 100/200 50%) 
33/71 46Yd 41/145 28%) 
2/82 2%) 12/171 7%) 
Chloroquine and cycloguanil 19/71 I I  27%) 321143 22%) Chloroquine C cloguanil d e  floquine 
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tivity patterns of isolates from cases of prophylactic 
failure (RINGWALD et al., 1990). 
Overall, resistance in vitro to chloroquine, cycloguanil, 
and mefloquine was observed in 5 I%, 33% and 5% of the 
isolates, respectively (Table 1). The mechanisms of ac- 
tion of chloroquine and cycloguanil and the mechanisms 
of resistance to these drugs are different. Furthermore, 
since cycloguanil has additional high activity against the 
hepatic stages, the drug combination should be more ef- 
fective in vivo than chloroquine alone (HOWELLS et al., 
1985). Several clinical studies have suggested the supe- 
riority of chloroquine plus proguanil over chloroquine 
alone (SARROUY et al., 1991; GARIN et al., 1993), contra- 
dicting the opinion of LOBEL et al. (1993). In comparison 
with chloroquine and cycloguanil, mefloquine resistance 
in vitro was observed in only a few isolates. Thus, assum- 
ing full compliance with the recommended regiméns, we 
should expect to see less breakthrough in travellers on 
mefloquine than in those on chloroquine-proguanil. 
Our extrapolation from the in vitro data to the expected 
effectiveness in vivo must be treated with caution. The 
limitations of the present study include the exclusion of 
pharmacokinetic factors, evaluation restricted to the 
blood schizontocidal activity of cycloguanil, and lack of 
complete information concerning compliance, side ef- 
fects, and prophylactic effectiveness in patients from 
whom the isolates were obtained. Inter-individual vari- 
ability in drug absorption as well as biotransformation of 
proguanil to cycloguanil in extensive and poor metabo- 
lizers may possibly result in prophylactic failure even 
with drug-sensitive parasites. Since cycloguanil is more 
active against the hepatic stages than against the intra- 
erythrocytic stages, an isolate that is cycloguanil-resistant 
during the intraerythrocytic stages may in fact be cyclo- 
guanil-sensitive in the hepatic stages (HOWELLS et al., 
1985). This observation implies that our study may have 
underestimated the efficacy of cycloguanil in vivo. In ad- 
dition, possible bias in our collection of African isolates 
must be considered since our hospitals (in Paris and Mar- 
seille) tend to recruit patients who are severely ill or in 
whom chemoprophylaxis or previous treatment has 
failed, thus increasing the proportion of drug-resistant 
isolates. 
Nevertheless, our study suggests that cycloguanil 
alone has high activity in vitro against most African iso- 
lates of P. falciparum, that there are a few isolates that 
are resistant in vitro to both chloroquine and cycloguanil, 
and that mefloquine-resistant isolates are rare in Africa. 
Despite the uncontestably high activity in vitro and 
proven clinical efficacy of mefloquine, the chloroquine- 
cycloguanil combination is active in vitro against a con- 
siderable proportion of African isolates and still has a 
place in the chemoprophylaxis of travellers visiting Af- 
rica, especially the western part of the continent. 
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Because proguanil is metabolized to a much more ac- 
tive triazine derivative, it has been assumed that effective 
malarial chemoprophylaxis depends upon the extent of 
Table. Concentration of proguanil and cycloguanil in 
urine of Japanese volunteers 6 h after an oral dose of 
200 mg proguanil 
Proguanil metabolizer statusa 
Extensive Poor 
No. of subjects 102 23 
Mean concentration 
Pro uanil/cycloguanil ratio 
Pro uanil( g/mL) 5.5k3.6 10.1k6.6 
Cycfoguanif(pg/mL) 1-7k 1.3 0.41kO-45 
dean  
Range 
4.0k2.2 41-6k32.9 
0.48-0.91 12.9-100b 
aA!l differences are significant at P<O.O5. 
bFive of the poor metabolizers had urinary cycloguanil 
concentrations below the minimum detection limit 
(0.001 pg/mL), and their proguaniVcycloguani1 ratio 
was ascribed a maximal value of 100. 
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